Search | Clinical Trials Finder

Conditions: Menopause, Arteriosclerosis
Interventions: Conjugated equine estrogens 0.45 mg/day, Transdermal estradiol, 50 mcg/day, Micronized progesterone, 200 mg/day x 12 d/month, CEE , progesterone, estradiol patch or placebo for each, CEE, progesterone, transdermal patch or the placebo; Drug
Lead sponsor: Kronos Longevity Research Institute; Other
Eligibility: 42 Years to 58 Years · Female only
Enrollment: 728 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2012
U.S. locations: 9
States / cities: Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 6 more

Conditions: Depressive Disorder, Major, Menopause
Interventions: Estrogen; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 40 Years to 60 Years · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer, Breast Cancer Female, Metastatic Triple-Negative Breast Carcinoma, ER Positive Breast Cancer, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, ER-negative Breast Cancer
Interventions: Datopotamab Deruxtecan; Drug
Lead sponsor: Nancy Lin, MD; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: Miami, Florida • Boston, Massachusetts • Durham, North Carolina

Conditions: Postmenopause
Interventions: Premarin; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 35 Years to 70 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Overactive Bladder, Incontinence, Nocturia
Interventions: Estrogen Cream; Drug
Lead sponsor: Loyola University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Endometriosis
Interventions: Norethindrone acetate + estrogens, norethindrone acetate + placebo; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 13 Years to 22 Years · Female only
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Menopause, Multiple Sclerosis
Interventions: Tissue Selective Estrogen Complex, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 62 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Nocturnal Vasomotor Symptoms
Interventions: SCE-B, Placebo; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 30 Years to 65 Years · Female only
Enrollment: 157 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 17
States / cities: Anaheim, California • Sacramento, California • San Diego, California + 14 more

Conditions: Pelvic Organ Prolapse, Menopause
Interventions: Premarin, Placebo; Drug · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Vaginal Atrophy
Interventions: Bazedoxifene/Conjugated Estrogen; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 63
States / cities: Birmingham, Alabama • Montgomery, Alabama • Scottsdale, Arizona + 60 more

Conditions: Menopause, Osteoporosis
Interventions: bazedoxifene 20 mg/ conjugated estrogens 0.45 mg, bazedoxifene 20 mg/ conjugated estrogens 0.625 mg, bazedoxifene 20 mg, conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 40 Years to 64 Years · Female only
Enrollment: 1,886 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 143
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 119 more

Conditions: Hormone Replacement Therapy
Interventions: Estradiol acetate, Estradiol, Conjugated equine estrogens; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 35 Years and older · Female only
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 32
States / cities: Phoenix, Arizona • Carmichael, California • San Diego, California + 28 more

Conditions: Breast Cancer
Interventions: Duavee; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: Up to 61 Years · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Kansas City, Kansas • Westwood, Kansas

Conditions: Osteoporosis
Interventions: BZA 20 mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg, Raloxifene 60 mg, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 507 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 22
States / cities: Fort Myers, Florida • Gainesville, Florida • New Port Richey, Florida + 19 more

Conditions: Menopause
Interventions: Synthetic Conjugated estrogens, B, Placebo; Drug · Other
Lead sponsor: Duramed Research; Industry
Eligibility: 30 Years to 80 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 38
States / cities: Huntsville, Alabama • Tucson, Arizona • Carmichael, California + 31 more

Conditions: Ovarian Failure, Premature
Interventions: 17beta Estradiol, Conjugated estrogens, 17Beta Estradiol - transdermal, Progesterone, micronized; Drug
Lead sponsor: Stanford University; Other
Eligibility: 12 Years to 18 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Stanford, California

Conditions: Coronary Heart Disease
Interventions: Premarin .625 mg daily plus medroxyprogesterone 2.5 mg daily; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 55 Years to 75 Years · Female only
Enrollment: 2,430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 2001
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Metastatic Breast Cancer, HER2 Low Breast Carcinoma, HER2-negative Breast Cancer, Breast Cancer, Breast Cancer Female
Interventions: Elacestrant, Trastuzumab Deruxtecan; Drug
Lead sponsor: Kristina A. Fanucci; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2038
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: high performance liquid chromatography, laboratory biomarker analysis, mass spectrometry, medical chart review; Other
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 2
States / cities: Rochester, Minnesota • Omaha, Nebraska

Conditions: Healthy
Interventions: Bazedoxifene/conjugated estrogens combination; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 35 Years to 70 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Overactive Bladder
Interventions: conjugated estrogen; Drug
Lead sponsor: Loyola University; Other
Eligibility: 55 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Ductal Breast Carcinoma In Situ, Postmenopausal
Interventions: Conjugated Estrogens/Bazedoxifene, Laboratory Biomarker Analysis, Pharmacological Study, Placebo, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other · Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 79 Years · Female only
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 10
States / cities: Aurora, Colorado • Chicago, Illinois • Geneva, Illinois + 7 more

Conditions: Postmenopause
Interventions: Premarin/MPA 0.45 mg/1.5 mg; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 35 Years to 70 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy
Interventions: CE/BZA, Itraconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 40 Years to 64 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 2
States / cities: Miami, Florida

Search by objective public record fields.

Kronos Early Estrogen Prevention Study (KEEPS)

Estrogen and Perimenopausal Depression

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

Study Evaluating Premarin and Bazedoxifene Potential Interaction

Investigation of the Effect of the Female Urinary Microbiome on Incontinence

The Effect of Hormonal Add-Back Therapy in Adolescents Treated With a GnRH Agonist for Endometriosis: A Randomized Trial

A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis

Study to Evaluate the Effects of Synthetic Conjugated Estrogens, B (SCE-B) on Nocturnal Vasomotor Symptoms in Postmenopausal Women

Effect of Preoperative Estrogen Treatment on Connective Tissues of the Pelvic Floor

Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause

Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis

Hormone Replacement Therapy for Use in Postmenopausal Women for Relief of Hot Flushes and Urogenital Symptoms.

Pilot Study of the Effect of Duavee® on Benign Breast Tissue Proliferation

Study Evaluating Changes In Mammographic Breast Density

A Clinical Trial to Evaluate the Safety and Efficacy of Enjuvia 0.3 mg for the Treatment of Vulvovaginal Atrophy

Comparison of Transdermal and Oral Estrogens in Adolescent Girls With Ovarian Failure

Heart and Estrogen-Progestin Replacement Study (HERS)

ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer

Effect of Tamoxifen or an Aromatase Inhibitor on Estrogen Metabolism in Women Treated for Newly Diagnosed Breast Cancer

Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations in Fed and Fasting in Healthy, Postmenopausal Women

The Estrogen Impact on Overactive Bladder Syndrome: Female Pelvic Floor Microbiomes and Antimicrobial Peptides

The PROMISE Study: Duavee in Women With DCIS

Bioequivalence Study of 3 New Formulations of Premarin/MPA Compared With Premarin/MPA (Prempro)

Study Evaluating Effects of Multiple-Dose Administration of Itraconazole on the Single Dose Pharmacokinetics of Conjugated Estrogens/Bazedoxifene in Non-Obese and Obese Postmenopausal Women